Nor Metrogyl

Quick links

Choose a section

Quick links to important sections

Advertisements

Nor Metrogyl

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Nor Metrogyl

Nor Metrogyl: Quick Identity Overview

Property Description
Active Ingredients Norfloxacin and Metronidazole
Form Oral Tablet (Fixed-Dose Combination)
Pharmacological Class Fluoroquinolone Antibiotic + Nitroimidazole Antimicrobial
Common Use Mixed Bacterial and Parasitic Infections
Origin Synthetic

Nor Metrogyl is the International Nonproprietary Name (INN) for a combined antimicrobial drug, typically formulated as a prescription-only oral tablet. This medicine is a Fixed-Dose Combination (FDC) product, blending two distinct synthetic compounds to provide broad coverage against microbial pathogens. Its unique characteristic is its strategic pairing of agents to target different classes of infectious organisms.


What is Nor Metrogyl’s Composition and Class?

The formulation is defined by its two active pharmaceutical ingredients: Norfloxacin and Metronidazole. These compounds belong to complementary drug classes to enhance therapeutic reach.

Norfloxacin is classified as a fluoroquinolone antibiotic, a class known to disrupt bacterial DNA synthesis. Metronidazole is an antimicrobial/antiprotozoal agent belonging to the nitroimidazole class, which is effective against anaerobic bacteria and specific protozoa. The dual composition is designed for use in polymicrobial diseases.


What is Nor Metrogyl Used to Treat? (General Purpose)

The general therapeutic purpose of Nor Metrogyl is to provide comprehensive treatment for mixed infections, particularly those affecting the gastrointestinal system. A typical scenario involves treating severe diarrheal diseases or dysentery caused by both bacterial and parasitic agents. The FDC tablet is a clinically recognized approach designed to ensure simultaneous, effective action against the diverse pathogens that often coexist in these types of infections.

Advertisements

What side effects are possible with Nor Metrogyl?

Possible Side Effects and Safety Information

The official safety profile for Nor Metrogyl, a combination of Norfloxacin (a fluoroquinolone) and Metronidazole (a nitroimidazole), is defined by the documented risks associated with both antimicrobial classes. Adverse reactions are formally classified by frequency and the physiological systems affected, including Gastrointestinal, Nervous System, and Musculoskeletal disorders.

Common adverse reactions listed in regulatory documents include nausea, headache, dizziness, and general abdominal discomfort. More severe or less common adverse reactions are explicitly documented in official labeling.


Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions (SARs) are highlighted in regulatory texts. The Norfloxacin component is associated with risks of tendinitis and potentially irreversible peripheral neuropathy, which can occur soon after treatment initiation or long after cessation. Metronidazole carries risks of serious Central Nervous System (CNS) events, including convulsive seizures and encephalopathy, and is associated with acute liver failure in rare cases.

Safety constraints require that alcohol consumption is prohibited during Metronidazole treatment and for at least 48 hours afterward, due to the risk of a severe reaction. Cautions are issued for specific populations; for instance, the risk of tendon issues is increased in older adults, and Metronidazole is contraindicated in patients with Cockayne syndrome due to rapid-onset hepatotoxicity. Official labeling advises that prolonged administration (over 10 days) may necessitate specific clinical monitoring, such as leukocyte counts.

Advertisements

Overdose and Emergency Response

Overdose involving Nor Metrogyl (Norfloxacin and Metronidazole) is associated with specific manifestations documented in regulatory sources. Symptoms often affect the central nervous system (CNS) and the gastrointestinal system. Documented overdose presentations include Nausea, Vomiting, Confusion, and Seizures (Convulsions). Other neurological effects noted are Hallucinations, Paranoia, Tremors, and Ataxia.

Severe outcomes reported following massive overexposure include Encephalopathy and the potential for Increased Pressure Inside the Skull. In rare cases, Kidney Failure has been associated with acute Norfloxacin overdosage. Immediate Medical Intervention is Required for any suspected overdose. The official prescribing information mandates that individuals seek emergency medical attention or call a Poison Help line right away. Urgent medical help must be sought if severe symptoms, such as a seizure or trouble breathing, are present.

Regulatory documents state that no specific antidote is known for Metronidazole overdose, and management is primarily symptomatic and supportive treatment. Procedural steps, such as gastric lavage, may be considered for recent acute overdosage. The patient must be carefully observed. Specific considerations exist for clearance: Metronidazole is efficiently removed by haemodialysis, while Norfloxacin is not dialysable. Patients with severe hepatic insufficiency face a higher risk of drug accumulation that may lead to encephalopathy.

Advertisements

Therapeutic Uses of Nor Metrogyl

Nor Metrogyl is a combination medication that may be prescribed for the management of specific bacterial and protozoal infections. It is intended to address conditions where organisms susceptible to both active components are present. This therapeutic option can help support the reduction of symptoms associated with infections affecting the gastrointestinal system, the urinary tract, and the reproductive organs.

It is indicated for infections such as bacterial diarrhea, amoebiasis, and certain gynecological infections. By targeting these susceptible microorganisms, the medication works to restore comfort and **support the body's natural recovery process.


Quick Fact: Relief for Gastrointestinal and Urinary Discomfort

Quick Fact: Relief for Gastrointestinal Discomfort and symptoms associated with susceptible bacterial or protozoal infections, including those affecting the urinary tract.

Advertisements

Eligibility and Restrictions for Use

Nor Metrogyl is a fixed-dose combination product containing Metronidazole and Norfloxacin, and its eligibility is governed by the contraindications and restrictions of both components, as defined in government regulatory documents.

Populations and Conditions that Must Not Use Nor Metrogyl (Contraindicated):

Classification Condition/Population
Allergy Known hypersensitivity to Metronidazole, Norfloxacin, or other nitroimidazole/fluoroquinolone drugs.
Genetic Disorder Patients with Cockayne syndrome (due to risk of severe liver failure).
Drug/Substance Use Concomitant use with Disulfiram (within two weeks) or alcohol (during treatment and for a period after).
Pregnancy Generally contraindicated during the first trimester.

Populations Requiring Restricted or Conditional Use:

  • Age: Safety and efficacy are not established in the pediatric population (children and adolescents under 18 years of age). Use in older adults requires caution due to a higher risk of adverse effects and age-related liver issues.
  • Organ Function: Patients with severe hepatic impairment (severe liver disease) or severe renal impairment (severe kidney disease or end-stage renal disease) require caution, dose reduction, and close monitoring due to slower drug clearance.
  • Pre-existing Conditions: Caution is required in patients with a history of seizures, peripheral neuropathy, or central nervous system disorders. Use is also restricted in patients with a history of tendinitis/tendon rupture linked to fluoroquinolone use, and those with Myasthenia Gravis.
Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Nor Metrogyl (Norfloxacin and Metronidazole) establishes specific constraints across several interaction domains, based on authoritative government labeling.

Formal Restrictions and Contraindications

Co-administration is formally prohibited with Disulfiram, requiring a two-week separation period. The combination with Tizanidine is also contraindicated due to the risk of increased Tizanidine exposure. Additionally, the Metronidazole component prohibits the consumption of Alcohol and products containing propylene glycol during therapy and for a minimum of three days afterward, owing to the potential for a disulfiram-like reaction.

Pharmacokinetic and Exposure Effects

The Norfloxacin component is a documented CYP1A2 inhibitor, leading to increased plasma concentrations of co-administered substrates, including Theophylline and Caffeine. Metronidazole potentiates the anticoagulant effect of Warfarin and other coumarin anticoagulants. Co-administration also results in increased serum concentrations of Lithium and Busulfan.

Timing and Absorption Requirements

Substances containing polyvalent cations (such as Iron, Aluminum, Magnesium, Zinc, found in antacids or supplements) and Sucralfate must not be taken within the two-hour period before or after Nor Metrogyl administration. This restriction prevents interference with Norfloxacin absorption.

Systemic and Population Notes

Pharmacodynamic effects include an increased risk of QTc prolongation when co-administered with other QTc-affecting medicines. Furthermore, regulatory documents note that reduced clearance of Metronidazole may lead to drug and metabolite accumulation in patients with Severe Hepatic Impairment.

Advertisements

Mechanism of Action

Dual Molecular Attack on Microbial DNA

The mechanism of action of Nor Metrogyl involves two distinct, concurrent molecular mechanisms that disrupt microbial nucleic acid synthesis. Norfloxacin (a fluoroquinolone) acts as an inhibitor of essential bacterial enzymes, DNA Gyrase and Topoisomerase IV, thereby causing lethal DNA double-strand breaks. Conversely, Metronidazole (a nitroimidazole) is a prodrug that, upon reductive activation inside susceptible cells, generates highly reactive cytotoxic radicals that chemically fragment microbial DNA. This dual action initiates an irreversible molecular sequence leading to microbial cell death.


Complementary Pathogen Spectrum and Activity

The combination's mechanisms lead to the destruction of a broad range of pathogens by utilizing the non-overlapping pathogen spectra of its components. Norfloxacin acts on aerobic and facultative anaerobic bacteria, while Metronidazole is selectively activated to destroy obligate anaerobic bacteria and specific protozoa. This mechanistic synergy contributes to the destruction of diverse microbial populations, resulting in the simultaneous elimination of these distinct pathogens from affected biological systems.


Activation Dependence and Limitations

The Metronidazole component’s mechanism is strictly dependent on the low redox potential found in the target cells; the presence of oxygen significantly impairs this reductive activation step, acting as a factor that limits the activation of the drug in aerobic systems. The overall mechanistic efficacy is also subject to microbial adaptations such as target site mutations (for Norfloxacin) or reduced capacity for drug activation (for Metronidazole).

Advertisements

Dosage and Administration Information

Official Administration and Dosing Guidelines

Nor Metrogyl is a Fixed-Dose Combination (FDC) oral tablet containing Norfloxacin (400 mg) and Metronidazole (500 mg). The instructions for its use are derived from the prescribing information for the combined product and its individual components.

Standard Administration Rules

The standard adult regimen involves taking one tablet twice daily (every 12 hours). Treatment is typically prescribed for a short, fixed course, often ranging from 5 to 10 days, and the full course must be completed as prescribed.

Instruction Detail Administration Guidelines
Route of Administration Strictly Oral (tablet to be swallowed whole).
Frequency Twice daily (every 12 hours).
Timing with Food May be taken with or immediately after a meal to help reduce potential gastrointestinal upset.
Cation Separation Must be taken at least two hours before or two hours after ingesting dairy products, antacids, or supplements containing polyvalent cations (calcium, iron, magnesium, or zinc), as these can reduce Norfloxacin absorption.

Dose Adjustments and Special Use

Prescribing information outlines high-level dose adjustments for specific patient populations to prevent drug accumulation:

  • Renal Impairment: For patients with significant reduction in kidney function (CrCl le 30 mL/min/1.73 m^2), the dosage of the Norfloxacin component is typically reduced (e.g., to once daily).
  • Severe Hepatic Impairment: A dosage reduction, often by 50%, is generally recommended for the Metronidazole component in patients with severe liver dysfunction (Child-Pugh C).
  • Missed Dose: If a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped; doses should not be doubled. Liberal fluid intake is advised during treatment.
Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nor Metrogyl


Evidence for Mixed Gastrointestinal Infections

The Norfloxacin/Metronidazole Fixed-Dose Combination (FDC) was studied for conditions characterized by outcomes related to systemic or functional imbalance and acute, disruptive episodes. The FDC was studied for conditions involving the presence of both bacterial and protozoal organisms. Research in this area included short-term Randomized Controlled Trials (RCTs) and comparative studies where the combination was observed in adult patients with acute diarrhea or dysentery. Researchers monitored both changes in patient-reported outcomes related to physical discomfort and microbiological endpoints, which involved assessing the clearance of the targeted pathogens.

Studies reported measurements of both the resolution of symptoms and the elimination of organisms over short follow-up periods. Research describes patterns observed across various comparative trials involving the FDC, single-agent therapy, or other regimens. Comparative evidence is lacking for the FDC against some established single-agent or combination regimens.

Contextual Research on Drug Components

The evidence base for the FDC is contextualized by the research on its two separate active components. Research examined Norfloxacin in the context of bacterial infections, such as those affecting the urinary tract, in historical RCTs. Separately, research examined Metronidazole's use in treating infections caused by anaerobic bacteria and protozoal diseases, such as amoebiasis, with findings widely described in numerous systematic reviews and trials. These individual component studies contribute to the broader evidence landscape by exploring how each drug was observed in studies against its susceptible organisms.

What Remains Uncertain in the Research Landscape

While research describes patterns observed during short-term treatment, certainty remains low regarding the overall clinical advantage of the fixed-dose combination over using the individual components separately or sequentially. The evidence quality varies across studies, as many of the foundational studies supporting the components may predate modern standards, and sample sizes were modest in some of the specific FDC trials. Furthermore, comparative evidence is lacking regarding the FDC against other established treatments. The evidence highlights what is known — and what is still uncertain — about the FDC's role.

Key Studies & References

  1. Fluoroquinolone Use in Urinary Tract Infections: Current Status and Regulatory Considerations
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Nor Metrogyl (FAQ)


Q: Can Nor Metrogyl be used to treat diarrhea or loose motions?

Regulatory information indicates that the components of Nor Metrogyl are used to treat infections that cause severe diarrheal illness or dysentery. The combination is typically used when the cause is suspected to involve both susceptible bacteria and protozoa (parasites). This determination is made by a healthcare provider based on the diagnosed cause of the diarrhea.

Q: Is Nor Metrogyl considered a broad-spectrum antibiotic?

Yes, this combination product is generally considered a broad-spectrum antimicrobial. This is because it combines Norfloxacin, which is effective against many aerobic bacteria, with Metronidazole, which targets anaerobic bacteria and specific protozoa. This strategic combination allows it to treat a wider range of different types of infectious organisms.

Q: What is the typical length of a treatment course with Nor Metrogyl?

Treatment duration can vary depending on the type and severity of the infection being treated. However, according to official prescribing information, the course is usually a short, fixed period. For many common infections, this duration is often around 7 to 10 days.

Q: Is it normal to experience a metallic or unpleasant taste in the mouth while taking Nor Metrogyl?

Yes, a metallic or unpleasant taste is a frequently reported side effect associated with the Metronidazole component of the medicine. This is a common, though temporary, sensory change that usually resolves once the course of medication is completed.

Q: Why does Nor Metrogyl sometimes cause a metallic taste?

This specific side effect is related to how the body processes the Metronidazole component. As the drug breaks down, its metabolic byproducts are partially excreted in the saliva, leading to the distinct metallic or altered taste sensation.

Q: Can Nor Metrogyl cause changes in sleep patterns or difficulty sleeping?

Official labeling for the components indicates that Central Nervous System (CNS) effects are possible. Difficulty falling or staying asleep, known as insomnia, is listed as a potential adverse reaction to this medication.

Q: Does Nor Metrogyl interact with blood thinners or diabetes medications?

Yes, the Metronidazole component can significantly increase the blood-thinning effects of medicines like Warfarin. Due to this known interaction, careful monitoring is typically required. Core regulatory documents do not consistently report a critical interaction with general diabetes medications, but caution is always advised.

Q: Can Nor Metrogyl be taken with or without food to minimize stomach upset?

Regulatory administration rules state that the tablet may be taken with a meal or immediately after eating. This is generally recommended as a way to help reduce the possibility of gastrointestinal side effects like nausea or stomach discomfort.

Q: Is there a risk of developing a secondary fungal or yeast infection (like oral thrush) after taking Nor Metrogyl?

As with most antimicrobial medications, there is a general risk of developing an overgrowth of non-susceptible organisms, such as Candida (yeast). This shift in the body's microbial balance can sometimes lead to secondary fungal infections like oral thrush or vaginal yeast infections.

Q: Is Nor Metrogyl the same as taking separate Metronidazole and Norfloxacin tablets?

While the Fixed-Dose Combination (FDC) contains the same active ingredients, it is approved as a single, combined tablet. FDCs are specifically formulated and approved by regulators to enhance patient adherence and simplify treatment, making the single tablet distinct from two separately prescribed medicines.

Q: What is the difference between Nor Metrogyl and plain Metronidazole (like Metrogyl)?

Plain Metronidazole contains only the nitroimidazole antimicrobial agent and is primarily used for anaerobic bacteria and protozoal infections. Nor Metrogyl is a combination product that adds Norfloxacin, a fluoroquinolone antibiotic, to target a much broader spectrum of infectious bacteria.

Q: What happens if a dose of Nor Metrogyl is accidentally missed?

Official administration instructions advise that a missed dose should be taken as soon as it is remembered. However, if it is already close to the time for your next scheduled dose, the missed dose should be skipped entirely. Doses should not be doubled to compensate for a missed dose.

Q: Does Nor Metrogyl cause dark or discolored urine?

Yes, a known, harmless side effect of the Metronidazole component is that it can cause the urine to appear darker, often described as reddish-brown. This is due to the drug's metabolic byproducts and is temporary.

Q: Can Nor Metrogyl make your skin more sensitive to the sun?

Yes, the Norfloxacin component, which belongs to the fluoroquinolone class, is associated with a risk of photosensitivity. Because of this risk, precautions such as limiting exposure to sunlight or UV light and using protective clothing are generally recommended while using this medicine.

Q: Is it common to feel unusually tired or fatigued while on Nor Metrogyl?

Fatigue or feeling unusually weak and tired is listed as a potential side effect in the official safety profile for the Norfloxacin component. If this side effect becomes severe or causes concern, consulting a healthcare professional is advised.

Q: Does taking Nor Metrogyl affect the body's natural gut bacteria?

Yes, as a broad-spectrum antimicrobial, this medicine works by killing susceptible bacteria, which can include some of the helpful bacteria that naturally live in the gut. This change in the normal balance can sometimes lead to gastrointestinal side effects.

Q: Is there any research on the effectiveness of Nor Metrogyl for long-term conditions?

The combination is typically intended and studied for short courses to treat acute infections. Official prescribing information advises that if administration is required for more than 10 days, specific clinical monitoring, such as blood tests, may be necessary.

Q: Can Nor Metrogyl be used to treat infections outside of the digestive tract, such as UTIs?

The Norfloxacin component is approved for treating infections in other areas, such as the urinary tract. However, the approved indications for the Nor Metrogyl combination as a whole depend on the specific regulatory approval of the fixed-dose product in your region.

Q: Why might a doctor prescribe Nor Metrogyl instead of a single-ingredient antibiotic?

The combination is typically prescribed when an infection is suspected to be 'mixed,' meaning it is caused by both aerobic bacteria and anaerobic organisms or protozoa. The dual-action formula is designed to ensure comprehensive coverage against these diverse pathogens simultaneously.

Q: Is it possible to develop antibiotic resistance if Nor Metrogyl is stopped too soon?

The risk of developing drug-resistant bacteria is a major concern with any antimicrobial. Official guidance strongly advises completing the full prescribed course, even if symptoms improve quickly, to ensure all susceptible pathogens are eliminated.

Q: Can Nor Metrogyl affect mental clarity or the ability to concentrate?

The components of this medicine have been linked to potential adverse effects on the Central Nervous System (CNS). These effects can include confusion, restlessness, or nervousness, which may temporarily impact your mental clarity and ability to concentrate.

Q: Is it normal to feel a tingling or numbness sensation in the hands or feet with this medicine?

Official labeling for the Norfloxacin component includes a serious warning about peripheral neuropathy, which is nerve damage that can cause symptoms like pain, burning, tingling, or numbness in the limbs. If these sensations occur, consulting a healthcare professional promptly is recommended.

Q: Are there any signs that the infection is getting worse while on Nor Metrogyl?

Consulting a healthcare provider is recommended if symptoms do not begin to improve within a few days of starting the medication. Additionally, any new or worsening severe symptoms, such as severe bloody diarrhea, fever, or rash, should prompt immediate medical attention.

Q: Does the brand of Nor Metrogyl (e.g., tablet vs. suspension) change its effectiveness?

The fixed-dose combination product is widely approved in its oral tablet form. While other formulations of its single components exist, the clinical effectiveness of any form is specific to the formulation and its approved use by regulatory authorities.

Q: Is the combination of Norfloxacin and Metronidazole considered a standard treatment protocol for certain infections?

The combination is a well-established and recognized approach in clinical practice for the treatment of mixed intestinal and diarrheal infections. It is considered a relevant option when comprehensive coverage against a diverse range of pathogens is needed.

Q: Does Nor Metrogyl cause weight loss or loss of appetite?

Loss of appetite, or anorexia, is listed as a common adverse reaction associated with the Metronidazole component of the medicine. This may contribute to temporary weight changes while you are taking the full course of treatment.

Q: Is Nor Metrogyl effective against viral infections?

No. Nor Metrogyl is an antimicrobial medication that is specifically designed to work against bacteria and protozoa (parasites). It has no effect on viral illnesses, such as the common cold, flu, or COVID-19.

Q: Can Nor Metrogyl interact with common over-the-counter pain relievers (NSAIDs)?

Official drug interaction warnings indicate that the Norfloxacin component can increase the risk of CNS excitation and potentially seizures when taken with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. It is important to discuss all pain relievers being taken with a healthcare provider.

Q: What are the common signs of an interaction between Nor Metrogyl and caffeine?

The Norfloxacin component can increase the concentration of caffeine in the body, intensifying its effects. Common signs of this interaction may include insomnia, nervousness, headache, and an increased heart rate.

Q: What are the specific storage requirements for Nor Metrogyl at home?

To maintain drug integrity, the medicine should be stored at controlled room temperature, which is typically between 20 C and 25 C. It must be kept in a tightly closed, light-resistant container and stored safely out of the sight and reach of children.

Q: Is there a maximum number of days Nor Metrogyl can be taken safely?

Treatment is intended to be for the minimum duration necessary to cure the infection, typically short-term (5-10 days). Regulatory documents caution that treatment lasting longer than 10 days may require close clinical monitoring by a healthcare provider.

Q: Does Nor Metrogyl make you hungry or affect your blood sugar?

While the drug is known to cause a loss of appetite, the Norfloxacin component is part of a class of drugs associated with rare cases of changes in blood glucose levels. If there are existing concerns about blood sugar, discussing this with a healthcare professional is advisable.

Advertisements

How should Nor Metrogyl be stored and disposed of?

Storage and Disposal Requirements

Official labeling for the components (Norfloxacin and Metronidazole) defines specific conditions required to maintain product integrity and safety.

Storage Conditions

Requirement Specification
Temperature Store at Controlled Room Temperature, typically 20 to 25 C (68 to 77 F).
Protection The medication must be protected from light and stored in a tight, light-resistant container that is kept tightly closed.
Child Safety Store the medicine out of the sight and reach of children. The container should use a child-resistant closure.

Disposal Instructions

Expired or unused tablets should not be flushed down a toilet or sink. Disposal should prioritize using an authorized drug take-back program. If this is unavailable, the unused product may be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash, following official guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nor Metrogyl found in:

A-Z Index: